ClinicalTrials.gg
CompletedNCT02079766Updated Sep 7, 2020Results posted

18F-AV-1451 and Florbetapir F 18 PET (Positron Emission Tomography) Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy

A Phase 2 interventional study of florbetapir F 18 and Flortaucipir F18 in Chronic Traumatic Encephalopathy, sponsored by Avid Radiopharmaceuticals. Completed at 2 sites in United States. Open to male participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-07.

Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Non-randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Chronic Traumatic Encephalopathy with a site in United States — 6 open to participants now, 6 under way, 1 of them phase 3. Chronic Traumatic Encephalopathy · United States.

Started
2014
with 1 other
Phase 2
3 of 15
1 open now
Registered
4th of 15
by date
Lead sponsor
1 of 15
Avid Radiopharmaceuticals

Among the 15 studies in Chronic Traumatic Encephalopathy with a site in United States, this one is one of 2 that started in 2014, is one of 3 in phase 2, and was the 4th registered.

Chronic Traumatic Encephalopathy

27 studies on the registry are indexed under Chronic Traumatic Encephalopathy; 11 are open to participants now.

Browse Chronic Traumatic Encephalopathy studies →

Open to participants now

6 of the 15 studies in Chronic Traumatic Encephalopathy with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Chronic Traumatic Encephalopathy studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.

This study: male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Chronic Traumatic Encephalopathy with a site in United States, or all of them as a file.
02

Study summary

This study will explore the use of flortaucipir as a biomarker for chronic traumatic encephalopathy (CTE) and examine the relationship between clinical presentation and tau deposition.

03

Conditions studied

  • Chronic Traumatic Encephalopathy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male subjects consented and currently enrolled in the Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests (DETECT) or the Long-Term Consequences of Repetitive Brain Injury in Athletes study protocols
  • Can tolerate up to two PET imaging sessions
  • Have the ability to provide for study procedures

Exclusion criteria

Exclusion Criteria:

  • Claustrophobia
  • Current cardiovascular disease or clinically significant abnormalities on screening
  • History of risk factors for Torsades de Pointes or are taking drugs known to cause -prolongation
  • Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer that the investigator believes would affect study participation or scan results
  • Have had a non-study related radiopharmaceutical imaging or treatment within 7 days prior to study PET imaging sessions
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    High Risk of CTE

    Flortaucipir PET scans in subjects at high risk of developing CTE (former National Football League players)

    Drug: florbetapir F 18 · Drug: Flortaucipir F18

  • Experimental
    Control

    Flortaucipir PET scans in former non-contact athletes

    Drug: florbetapir F 18 · Drug: Flortaucipir F18

Interventions

  • 370 megabecquerel (MBq) IV single-dose

    Also known as: Amyvid, 18F-AV-45

  • 370 megabecquerel (MBq) IV single-dose

    Also known as: T807, 18F-AV-1451, LY3191748

06

What researchers measure

Primary outcomes

  1. Flortaucipir Visual Read as CTE Biomarker

    Flortaucipir uptake was rated visually by sponsor expert reader as 'No Uptake', 'Mild Uptake', 'Moderate Uptake', or 'Intense Uptake'.

    Time frame: Baseline scan

  2. Relationship Between Clinical Presentation and Tau Deposition (Subjects at High Risk of CTE Only)

    The relationship between flortaucipir uptake and clinical presentation, as measured by the Mini-Mental State Examination (MMSE). Mini-mental status exam is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment. Specified in statistical analysis plan to only be conducted in High Risk of CTE group.

    Time frame: baseline scan

07

Results

Posted Sep 7, 2020

Participant flow

Subjects were recruited between June 2014 and October 2015 from the DETECT study (National Institutes of Health grant R01NS078337) and the Arizona Alzheimer's Consortium ("Long-Term Consequences of Repetitive Brain Injury in Athletes: A Longitudinal Study with Eventual Brain Donation")

Participant flow — Overall Study
MilestoneHigh Risk of CTEControls
Started3011
Completed2811
Not completed20
Withdrew: Physician decision10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryFlortaucipir Visual Read as CTE Biomarker

Flortaucipir uptake was rated visually by sponsor expert reader as 'No Uptake', 'Mild Uptake', 'Moderate Uptake', or 'Intense Uptake'.

Time frame:
Baseline scan
Reported as:
Count of participants · Participants
Flortaucipir Visual Read as CTE Biomarker
ParticipantsHigh Risk of CTEControls
No Uptake2311
Mild Uptake50
Moderate Uptake00
Intense Uptake00
Statistical analysis
  • High Risk of CTE vs Controls · Fisher Exact · p = 0.2959 (No adjustments for multiple comparisons or multiplicity were made for this study. No a priori threshold for significance was chosen.)
PrimaryRelationship Between Clinical Presentation and Tau Deposition (Subjects at High Risk of CTE Only)

The relationship between flortaucipir uptake and clinical presentation, as measured by the Mini-Mental State Examination (MMSE). Mini-mental status exam is a 30-point questionnaire that is used to measure cognitive impairment. Scores range from 0 to 30 with lower scores representing greater levels of cognitive impairment. Specified in statistical analysis plan to only be conducted in High Risk of CTE group.

Time frame:
baseline scan
Reported as:
Least squares mean · score on a scale
Relationship Between Clinical Presentation and Tau Deposition (Subjects at High Risk of CTE Only)
score on a scaleHigh Risk of CTE
No Uptake27.348 (26.625 to 28.071)
Mild Uptake26.800 (25.249 to 28.351)
Statistical analysis
  • High Risk of CTE · ANOVA · p = 0.5163 (No adjustments for multiple comparisons or multiplicity were made for this study. No a priori threshold for significance was chosen.)MMSE score as the response variable and flortaucipir uptake score (4 levels) as the fixed effect

Adverse events

Collected over End of study for AE reporting was 48 hours after the last study drug administration.. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Risk of CTE0/29 (0%)0/29 (0%)11/29 (37.9%)
Controls0/11 (0%)0/11 (0%)5/11 (45.5%)
Most frequent other events
Most frequent other events
EventHigh Risk of CTEControls
headacheNervous system disorders4/292/11
muscle spasmsMusculoskeletal and connective tissue disorders0/292/11
dizzinessNervous system disorders0/291/11
nauseaGastrointestinal disorders2/290/11
oral painGastrointestinal disorders2/290/11
diarrhoeaGastrointestinal disorders1/290/11
musculoskeletal discomfortMusculoskeletal and connective tissue disorders1/290/11
fatigueGeneral disorders1/290/11

Baseline characteristics

Includes all subjects who received at least one dose of florbetapir or flortaucipir

Age, Continuous
Age, Continuous(years)High Risk of CTEControlsTotal
Mean58.5 ± 8.2757.4 ± 6.2558.2 ± 7.71
Sex: Female, Male
Sex: Female, Male(Participants)High Risk of CTEControlsTotal
Female000
Male291140
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)High Risk of CTEControlsTotal
Hispanic or Latino000
Not Hispanic or Latino291140
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)High Risk of CTEControlsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American14115
White141024
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)High Risk of CTEControlsTotal
United States291140
MMSE
MMSE(units on a scale)High Risk of CTEControlsTotal
Mean27.2 ± 1.6428.6 ± 0.9227.6 ± 1.60
Amyloid status
Amyloid status(Participants)High Risk of CTEControlsTotal
Amyloid positive303
Amyloid Negative251136
08

Study locations

2 sites
  • Banner Alzheimer's Institute
    Phoenix, Arizona 85006, United States
  • Boston University
    Boston, Massachusetts 02118, United States
09

References and documents

Publications

  • Stern RA, Adler CH, Chen K, Navitsky M, Luo J, Dodick DW, Alosco ML, Tripodis Y, Goradia DD, Martin B, Mastroeni D, Fritts NG, Jarnagin J, Devous MD Sr, Mintun MA, Pontecorvo MJ, Shenton ME, Reiman EM. Tau Positron-Emission Tomography in Former National Football League Players. N Engl J Med. 2019 May 2;380(18):1716-1725. doi: 10.1056/NEJMoa1900757. Epub 2019 Apr 10. PubMed 30969506 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Oct 2015 and a completion of Oct 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 4 years 11 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2014
First posted
Mar 6, 2014
Start
Jun 2014
Primary completionActual
Oct 2015
CompletionActual
Oct 2015
Results delay requested
Feb 8, 2017
Results first posted
Sep 7, 2020
Last update
Sep 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02079766
Responsible party
Sponsor
First posted
Mar 6, 2014
Start date
Jun 2014
Primary completion
Oct 2015
Completion
Oct 2015
Results posted
Sep 7, 2020
Last update
Sep 7, 2020

Study contacts

Chief Medical Officer
study chair · Avid Radiopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flortaucipir

Start the discussion